Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
SELLAS Life Sciences Group ( (SLS) ) has issued an announcement.
SELLAS Life Sciences has reached a significant milestone in its Phase 3 REGAL trial for the treatment of acute myeloid leukemia with its lead product candidate, galinpepimut-S (GPS). The Independent Data Monitoring Committee will conduct an interim analysis to assess the drug’s efficacy, safety, and futility, following the achievement of a pre-specified threshold of 60 events. This development is crucial as it could potentially bring a new treatment option for AML patients, highlighting the dedication of the company and its stakeholders in advancing cancer therapeutics.
More about SELLAS Life Sciences Group
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapeutics for a broad range of cancer indications. Their lead product, galinpepimut-S (GPS), targets the WT1 protein in various tumor types and is being developed as both a monotherapy and in combination with other therapies. The company is also developing SLS009, a small molecule CDK9 inhibitor.
YTD Price Performance: 2.83%
Average Trading Volume: 782,410
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $76.72M
See more data about SLS stock on TipRanks’ Stock Analysis page.
